RETHINK LIMITS

WITH RUBRACA

ARIEL3 Efficacy

Rubraca significantly extended PFS and demonstrated anti-tumor efficacy
See The Data
Medical shield icon

Well-Established Safety
and Tolerability Profile

The majority of adverse reactions and lab abnormalities were Grades 1 or 21
See Safety Profile
Checklist icon

Rubraca
Resources

Downloadable resources and videos for your patients and practice
Get Resources

Discover the Importance of PARPi Maintenance Therapy for
Your Patients With Recurrent Ovarian Cancer1

Icon of 3 out of 4 women representing that 75% of women with ovarian cancer are diagnosed at an advanced stage

Figure references.6-9

Icon of 4 out of 5 women representing that 80% of patients with advanced ovarian cancer will have a recurrence

Figure references.6-9

ARIEL3 Trial Design

The largest pivotal phase 3 trial of a PARP inhibitor as a maintenance therapy for recurrent ovarian cancer1,2

See The Trial
  • aBased on 60% of estimated incidence for 2019 from the National Cancer Institute SEER Statistics.
  • BRCA, breast cancer susceptibility gene; BRCAwt, BRCA wild-type; HR, homologous recombination; HRd, HR-deficient; HRp, HR-proficient; PFS, progression-free survival; PARPi, poly(ADP-ribose) polymerase inhibitor.

Contact Clovis Oncology

Please fill out the form below to be contacted by a Clovis Oncology representative

*This field is required

*Mandatory

By submitting this form, you agree to allow Clovis Oncology Inc. to collect the information provided and to receive product and disease-state information from Clovis, our affiliates, service providers, and co-promotion partners by phone, email, or mail. Clovis or third-party partners working on our behalf will not sell, rent, or otherwise distribute your name and any personally identifiable information. We may share your information with our partners in accordance with our Terms of Use and Privacy Policy.

The information contained in this website is intended for U.S. healthcare professionals only.

By clicking the button below, you acknowledge that you are a U.S. healthcare professional.